Suppr超能文献

经房间隔瓣中瓣经导管二尖瓣置换术的分步指南。

A step-by-step guide to transseptal valve-in-valve transcatheter mitral valve replacement.

作者信息

Harloff Morgan T, Chowdhury Muntasir, Hirji Sameer A, Percy Edward D, Yazdchi Farhang, Shim Hunbo, Malarczyk Alexandra A, Sobieszczyk Piotr S, Sabe Ashraf A, Shah Pinak B, Kaneko Tsuyoshi

机构信息

Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.

出版信息

Ann Cardiothorac Surg. 2021 Jan;10(1):113-121. doi: 10.21037/acs-2020-mv-104.

Abstract

With the recent success of transcatheter aortic valve replacement (TAVR), transcatheter options for the management of mitral valve pathology have also gained considerable attention. Valve-in-valve (ViV) transcatheter mitral valve replacement (TMVR) is one such technique that has emerged as a safe and effective therapeutic option for patients with degenerated mitral valve bioprostheses at high-risk for repeat surgical mitral valve replacement. Several access strategies, including trans-apical, transseptal, trans-jugular, and trans-atrial access have been described for ViV-TMVR. Initial experiences were performed primarily via a trans-apical approach through a left mini-thoracotomy because it offers direct access and coaxial device alignment. With the advancements in TMVR technology, such as the development of smaller delivery catheters with high flexure capabilities, the transseptal approach via the femoral vein has emerged as the preferred option. This technique offers the advantages of a totally percutaneous approach, avoids the need to enter the thoracic cavity or pericardial space, and provides superior outcomes compared to a trans-apical approach. In this review, we outline key aspects of patient selection, imaging, procedural techniques, and examine contemporary clinical outcomes of transseptal ViV-TMVR.

摘要

随着经导管主动脉瓣置换术(TAVR)近期取得成功,用于治疗二尖瓣病变的经导管治疗方法也备受关注。瓣中瓣(ViV)经导管二尖瓣置换术(TMVR)就是这样一种技术,对于有再次进行外科二尖瓣置换术高风险的退化性二尖瓣生物假体患者而言,它已成为一种安全有效的治疗选择。对于ViV-TMVR,已描述了多种入路策略,包括经心尖、经房间隔、经颈静脉和经心房入路。最初的经验主要是通过左前外侧小切口经心尖入路进行的,因为它提供了直接入路和同轴器械对齐。随着TMVR技术的进步,如开发出具有高弯曲能力的更小输送导管,经股静脉的经房间隔入路已成为首选方案。该技术具有完全经皮入路的优点,无需进入胸腔或心包腔,并且与经心尖入路相比能提供更好的结果。在本综述中,我们概述了患者选择、成像、手术技术的关键方面,并审视经房间隔ViV-TMVR的当代临床结果。

相似文献

引用本文的文献

10
Multimodality Imaging in Valvular Structural Interventions.瓣膜结构干预中的多模态成像
Card Fail Rev. 2022 Nov 18;8:e31. doi: 10.15420/cfr.2022.10. eCollection 2022 Jan.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验